Recent 8-K filings for VKTX

• July 29, 2026, 4:05 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M

  Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.

• April 29, 2026, 7:59 PM ET earnings materiality 0.90 neutral item 2.02item 9.01 ◈ Earnings Releases

  Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled

  Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.

• February 11, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26

  Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).

• October 22, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track

  Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.

• August 19, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial

  Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).

• July 23, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway

  Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.

• April 23, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25

  Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.

• March 11, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 2.03item 8.01item 9.01

  Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply

  Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.

• February 5, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25

  Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.

• November 4, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing

  Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.

• October 23, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809

  Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.

• July 24, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M

  VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.

• June 4, 2024, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)

  NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).

• April 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M

  Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.

• March 26, 2024, 7:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss

  Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735

• March 4, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Viking Therapeutics closes $632.5M public offering of 7.44M shares at $85.00

  Closed public offering of 7,441,650 shares at $85.00 each, including full exercise of underwriters' option for 970,650 additional shares.

• March 1, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Viking Therapeutics prices $550M public offering of 6.47M shares at $85/share

  Gross proceeds ~$550M from 6.47M shares at $85; underwriters have 30-day option for 970,650 additional shares.

• February 27, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss

  Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.

• February 7, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Viking Therapeutics reports Q4 net loss $24.6M, cash $362M; key trial data due 1Q24

  Net loss Q4 $24.6M ($0.25/sh) vs $19.6M ($0.26) YoY; full year loss $85.9M.

• October 25, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled

  Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.

• July 26, 2023, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M

  VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.

• April 26, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Viking Therapeutics Q1 net loss $19.5M; VK2735 shows up to 7.8% weight loss

  Net loss $19.5M ($0.25/sh) vs $16.1M ($0.21/sh) in Q1 2022; R&D $11.0M, G&A $9.5M.

• April 3, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Viking Therapeutics closes $287.5M public offering of 19.8M shares at $14.50/share

  Gross proceeds of approximately $287.5 million from 19,828,300 shares at $14.50 per share.

• March 31, 2023, 7:59 PM ET other material materiality 0.70 positive item 1.01item 8.01item 9.01 ◈ Material Agreements

  Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50

  Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.

• March 28, 2023, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023

  Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.

• March 28, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023

  Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.

• February 8, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023

  Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.

• July 27, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track

  Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.

• April 27, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing

  Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.

• November 3, 2021, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing

  Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

17 positive 1 negative 23 neutral

source · VKTX on sec.gov